Added to YB: 2024-11-07
Pitch date: 2024-11-05
MRK [bullish]
Merck & Co., Inc.
+18.33%
current return
Author Info
Long-Term Pick shares in-depth stock analysis on high-quality stocks with growth potential. Sign up for the newsletter.
Company Info
Merck & Co., Inc. operates as a healthcare company worldwide. It offers human health pharmaceutical for various areas under the Keytruda, Keytruda Qlex, Welireg, Gardasil, ProQuad, M-M-R II, Varivax, Vaxneuvance, Capvaxive, RotaTeq, Pneumovax 23, Bridion, Prevymis, Dificid, Zerbaxa, Winrevair, Adempas/ Verquvo, Ohtuvayre, Lagevrio, Isentress/Isentress HD, Delstrigo, Pifeltro, Belsomra, Januvia, and Janumet brands.
Market Cap
$280.2B
Pitch Price
$97.93
Price Target
148.54 (+28%)
Dividend
3.00%
EV/EBITDA
10.81
P/E
31.73
EV/Sales
4.92
Sector
Pharmaceuticals
Category
value
Merck: Large Value Company Currently Undervalued
MRK: High-quality pharma co. w/ strong oncology portfolio (Keytruda 50% of pharma rev). Q3 rev +4% YoY to $16.7B. Keytruda sales +21% to $7.4B. Diversifying via acquisitions. 10x fwd P/E, 31% undervalued. Risks: Keytruda patent expiry 2028, price regulations. 7% rev growth, 10% total growth expected. $148.54 price target.
Read full article (10 min)